By Melissa Lipman ( February 23, 2015, 5:56 PM EST) -- The Federal Trade Commission on Monday signed off on Novartis AG's $16 billion acquisition of GlaxoSmithKline PLC's oncology business on the condition that Swiss pharmaceutical giant shed certain skin cancer drugs, bringing the companies one step closer to finalizing their $23 billion three-part deal....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.